- Home
- OM vs ALVR Comparison
OM vs ALVR Comparison
Compare OM & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OM
- ALVR
- Stock Information
- Founded
- OM 2003
- ALVR 2013
- Country
- OM United States
- ALVR United States
- Employees
- OM N/A
- ALVR N/A
- Industry
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OM Health Care
- ALVR Health Care
- Exchange
- OM Nasdaq
- ALVR Nasdaq
- Market Cap
- OM 44.0M
- ALVR 52.2M
- IPO Year
- OM 2020
- ALVR 2020
- Fundamental
- Price
- OM $1.14
- ALVR $0.40
- Analyst Decision
- OM Buy
- ALVR Sell
- Analyst Count
- OM 4
- ALVR 5
- Target Price
- OM $4.38
- ALVR $1.00
- AVG Volume (30 Days)
- OM 809.6K
- ALVR 366.0K
- Earning Date
- OM 02-19-2025
- ALVR 11-12-2024
- Dividend Yield
- OM N/A
- ALVR N/A
- EPS Growth
- OM N/A
- ALVR N/A
- EPS
- OM N/A
- ALVR N/A
- Revenue
- OM $114,729,000.00
- ALVR N/A
- Revenue This Year
- OM N/A
- ALVR N/A
- Revenue Next Year
- OM $10.83
- ALVR N/A
- P/E Ratio
- OM N/A
- ALVR N/A
- Revenue Growth
- OM N/A
- ALVR N/A
- 52 Week Low
- OM $0.44
- ALVR $0.40
- 52 Week High
- OM $5.88
- ALVR $1.05
- Technical
- Relative Strength Index (RSI)
- OM 59.79
- ALVR 27.58
- Support Level
- OM $0.96
- ALVR $0.40
- Resistance Level
- OM $1.23
- ALVR $0.53
- Average True Range (ATR)
- OM 0.16
- ALVR 0.04
- MACD
- OM -0.02
- ALVR 0.00
- Stochastic Oscillator
- OM 46.53
- ALVR 1.35
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company. It has developed a machine, Tablo, which reduces the cost and complexity of dialysis. Tablo provides Renal Replacement Therapy in Hospitals, Chronic Care in Dialysis Clinics and Home Dialysis.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.